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SpirometryAbstract Background: Chronic obstructive pulmonary disease (COPD) is a major cause of respi-
ratory morbidity and mortality worldwide. One of the main hypotheses concerning the pathogenesis
of emphysema, a key cause of morbidity and mortality in COPD, is the protease antiprotease imbal-
ance. Irreversible airﬂow obstruction in Chronic Obstructive Pulmonary Disease (COPD) is
thought to result from airway remodeling associated with aberrant inﬂammation.
This study examined changes in sputum as regards MMP-9, TIMP-1 and levels of inﬂammatory
cells in COPD patients compared with sputum of healthy smokers and non smokers.
Methods: Forty patients were included in this study. FEV1 before and after salbutamol inhala-
tion, MMP-9, TIMP-1 and inﬂammatory cell count in the sputum of COPD patients, healthy smok-
ers and non- smokers were investigated.
Results: MMP-9 was signiﬁcantly increased in both COPD patients (194.4 ± 100.6), and
healthy smokers (104.5 ± 42.1) compared with healthy non smokers (34.5 ± 36.1). TIMP-1 was
increased more in healthy non-smokers (192.7 ± 37.7) than COPD patients (115 ± 55.5) and
healthy smokers (145.3 ± 35.1). MMP-9/TIMP-1 was high in COPD patients (1.7 ± 0.9) and
healthy smokers (0.7 ± 0.3) compared with healthy non smokers (0.2 ± 0.2). Mean sputum total
leucocytic count (TLC) was highly statistically signiﬁcantly different between the three groups.
COPD group showed the highest means value while non smokers group showed the lowest one.
Conclusions: COPD is characterized by an imbalance between MMP-9 and TIMP-1 which may
play an important role in the pathogenesis of tissue remodeling and airway obstruction.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.
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Chronic Obstructive Pulmonary Disease (COPD) is a common
preventable and treatable disease characterized by persistent
airﬂow limitation that is usually progressive and associated
with an enhanced chronic inﬂammatory response in the air-
ways and the lung to noxious particles or gases [1]. COPD is
more common in smokers and ex-smokers than in nonsmok-
ers. Cigarette smokers have more respiratory symptoms, lung
function abnormalities, decline in FEV1, and COPD mortality
than non-smokers. The starting age, total pack-years smoked
and current smoking status are predictive of COPD morbidity
and mortality [2]. COPD is a classic disease of airway damage
and remodeling. Extracellular matrix (ECM) deposition is one
pathological form of the tissue remodeling detected in the air-
ways [3–5]. Matrix metalloproteinases (MMPs) have an impor-
tant role in the breakdown of ECM and they are considered as
biomarkers of tissue damage in several smoking related lung
diseases [4–6].
MMPs are a family of zinc containing endopeptidases,
which is a subset of the metzincin superfamily of metallopro-
teinases. These regulatory proteases are the extracellular
matrix (ECM) remodelers characterized by their substrate
speciﬁcity to degrade ECM proteins [7]. Approximately 20 dif-
ferent types of MMPs have been discovered and classiﬁed
based on their pre-synthetic region on chromosomes and their
various substrate speciﬁcities. Number designations MMP-1 to
MMP-28 are used for classiﬁcation [8]. Many of MMPs are
activated by smoking and/or oxidative stress [9,10]. They are
produced by a range of stromal cells and by two of the major
inﬂammatory cells implicated in COPD – neutrophils and alve-
olar macrophages [11,12]. MMPs can be separated into 6 main
classes according to their substrate speciﬁcity, cellular location
and primary structure: collagenases, gelatinases, stromelysins,
matrilysins, membrane-type MMPs and others [13,14]. Recent
studies have shown that levels of MMPs, especially MMP-9,
are elevated in the broncho alveolar lavage (BAL) ﬂuid from
patients with COPD, compared to normal controls [11,12],
and high levels of both MMP-9 and its cognate inhibitor
TIMP-1 have been found in sputum from chronic bronchitis
[15] and correlated with decrease in lung function [16,17].
MMP-9 may play important physiologic roles in lung extracel-
lular matrix remodeling and repair, and in regulating the lung
inﬂammatory response to injury [18]. However, MMP-9 has
also been implicated in the pathogenesis of various lung dis-
eases including chronic obstructive pulmonary diseases
[11,19,20].
Tissue inhibitors of metalloproteinases are a family of
secretory proteins that are able to inhibit matrix metallopro-
teinase activities through non-covalent binding of pre- or
active forms of MMPs at molar equivalence. By inhibiting
MMPs, TIMPs may inﬂuence also MMP-mediated processes
such as processing of cytokines, degradation of growth factor
binding proteins, and the release of ECM-bound growth fac-
tors [21–24]. Tissue inhibitors of matrix metalloproteinases
(TIMP) make up a family of four inhibitors (TIMP-1, -2, -3
and -4) [25]. All members of the TIMP-family inhibit MMPs
by forming covalent 1:1 complexes [13,26], and selective inhibi-
tion of some of the MMPs exists [27].The actions of TIMPs are
not restricted to MMP-inhibition, and their effect depends on
the cell context and model studied. TIMPs can modulatecellular processes such as cell growth, apoptosis and migration,
and can be both anti- and protumourigenic [13,26,27]. TIMP-1
works as a natural inhibitor of MMP-9 and is found in most
tissues and body ﬂuids. By inhibiting MMPs activities, TIMPs
are involved in tissue remodeling and regulation of ECM
metabolism. The TIMP family consists of four members shar-
ing important structural features as well as the ability of MMP
inhibition [13].
Induced sputum (IS) collection is a non-invasive method
for the assessment of inﬂammation in the airways [28,29].
Healthy smokers had a higher concentration of total MMP-9
and that concentration was correlated with their exposure to
tobacco smoke. Maintenance of the active MMP-9/TIMP-1
ratio in healthy smokers may explain the absence of progres-
sive airway obstruction [30].
Subjects methods
Subjects
Forty subjects were included in this study and were classiﬁed
into the following three groups: Group I (COPD group):
included 20 patients with smoking related clinically stable
COPD [using (GOLD2013) criteria]. These patients had a stable
airﬂow limitation with FEV1/FVC < 70% predicted with a
reversibility of <12% predicted followed by inhaled b2-agonist
administration. COPD group was classiﬁed as mild, moderate,
severe and very severe according to GOLD, 2013 classiﬁcation
as follows: mild COPD (FEV1P 80% predicted) with FEV1/
FVC< 0.70, moderate COPD (50% 6 FEV1 < 80%) with
FEV1/FVC < 0.70, severe COPD (30% 6 FEV1 < 50%) with
FEV1/FVC < 0.70, very severe COPD (FEV1 < 30% pre-
dicted) with FEV1/FVC < 0.70. Patients were excluded if they
had a history of respiratory disease other than COPD and respi-
ratory tract infection during the last 4 weeks before the study.
Group II (Healthy smokers group): included 10 subjects with
smoking history and normal FEV1 >70% of predicted and no
medical history of lung disease.Group III (Healthy non smokers
group): included 10 subjects who never smoked before. The
patients included in this study were inpatients in the Benha uni-
versity hospital.
Methods
A written informed consent was obtained from all subjects. All
the three groups underwent full history taking including his-
tory of smoking (current, ex, and non smoking), history of
chest symptoms (cough, expectoration, wheezes and dyspnea),
number of exacerbation in the last year and history of any
other co morbidities. Also full clinical examination (general,
full local respiratory system examination including inspection,
palpation, percussion and auscultation, with special regards to
manifestations of right sided heart failure as lower limbs
edema, congested neck veins, tenderness over right hypochon-
drium, and dullness on right parasternal area) and chest X ray.
Physiological assessment was also done using spirometry.
Flow/volume loop was performed to all cases. The test was
done before and 20 min after 2 puffs of Salbutamol (200 lg)
via a metered dose inhaler for the COPD group. All data were
expressed in percent of predicted value (FEV1%, FVC%,
FEV1/FVC%). Sputum induction was done and was processed
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(MMP-9 BIOTRAK ELISA), tissue inhibitor of metallopro-
teinase-1(TIMP-1) by ELISA (TIMP-1 BIOTRAK ELISA),
cytological examination and cellular count. The total and the
differential cell counts were expressed as corrected percentage.
Routine laboratory investigations (CBC, Liver enzymes, serum
creatinine) were also done.
Sputum induction and processing
Sputum was collected either spontaneously or induced with
hypertonic saline nebulization from all subjects. Prior to
sputum induction, patients inhaled 200 lg of salbutamol to
minimize broncho-constriction during the induction proce-
dure. Sputum was induced by inhalation of 3% hypertonic sal-
ine solution for 5 min (DeVilbiss 65 ultrasonic nebulizer;
DeVilbiss, Somerset, PA, USA), and the subjects were encour-
aged to cough and expectorate sputum into sterile containers
between each dose of nebulized saline. This procedure contin-
ued until an adequate sample containing >0.5 ml visible
mucocellular material was obtained. If a satisfactory sputum
sample was not obtained at the time the FEV1 had fallen
>20% compared to baseline values occurred or if troublesome
symptoms appeared the procedure should be stopped [31]. The
sputum was processed with Dithiothreitol (sputolysin) at a
ﬁnal concentration of 0.1% and then sputum diluted and cen-
trifuged (1500 rpm) [32] and the supernatants was collected.
The levels of MMP-9 and TIMP-1 of the sputum were mea-
sured with enzyme-linked immunosorbent assay (ELISA). Cell
viability was assessed in unﬁxed cells by Trypan blue staining
and Hemocytometry. A differential cell count of Neutrophils,
Macrophages, Eosinophils and Lymphocytes cells was then
performed using the May–Gru¨nwald–Giemsa stain.
The assay of matrix metalloproteinases-9 in sputum is done by
ELISA
Principles of assay
The RayBio human MMP-9 ELISA (enzyme-linked immu-
nosorbent assay) kit is an in vitro enzyme-linked immunosor-
bent assay for the quantitative measurement of human
MMP-9. This assay employs an antibody speciﬁc for human
MMP-9 coated on a 96-well plate. Standards and samples
are pipetted into the wells and MMP-9 present in the sample
is bound to the wells by the immobilized antibody. The wells
are washed and biotinylated anti-human MMP-9 antibody is
added. After washing away unbound biotinylated antibody,
HRP-conjugated streptavidin is pipetted to the wells. The wells
are again washed, a TMB substrate solution is added to the
wells and color develops in proportion to the amount of
MMP-9 bound. The stop solution changes the color from blue
to yellow, and the intensity of the color is measured at 450 nm
[33].
Assay procedure
All reagents and samples were brought to room temperature
(18–25 C) before use. 100 ll of each standard (see
Reagent Preparation step 2) and sample were added into
appropriate wells. Covered well and incubated for 2.5 h atroom temperature. The wells were washed 4 times with 1·
wash solution (200 ll each). 100 ll of 1· prepared biotinylated
antibody was added to each well and incubated for 1 h at room
temperature. The solution was discarded and washed 4 times
with 1· wash solution (200 ll each). 100 ll of prepared
Streptavidin solution was added to each well and incubated
for 45 min at room temperature. The solution was discarded
and washed 5 times with 1x wash solution (200 ll each).
100 ll of TMB One-Step Substrate Reagent was added to each
well and incubated for 30 min at room temperature in the
dark. 50 ll of Stop Solution was added to each well then the
absorbance was read at 450 nm immediately.
Calculation of results
The concentration of MMP-9 was calculated from standard
curve.
The assay of tissue inhibitor metalloproteinases-1in sputum is
done by ELISA
Principles of assay
TheRayBio humanTIMP-1 ELISA (enzyme-linked immuno-
sorbent assay) kit is an in vitro enzyme-linked immunosorbent
assay for the quantitative measurement of human TIMP-1. This
assay employs an antibody speciﬁc for human TIMP-1 coated
on a 96- well plate. Standards and samples are pipetted into
the wells and TIMP-1 present in the sample is bound to the wells
by the immobilized antibody. The wells are washed and biotin-
ylated anti-human TIMP-1 antibody is added. After washing
away the unbound biotinylated antibody, HRP-conjugated
Streptavidin is pipetted into the wells. The wells are washed
again, and a TMB substrate solution is added to the wells and
color develops in proportion to the amount of TIMP-1 bound.
The stop solution changes the color from blue to yellow, and the
intensity of the color is measured at 450 nm [34].
Assay procedure
All reagents and samples were brought to room temperature
(18–25 C) before use. 100 ll of each standard (see Reagent
Preparation step 2) and sample were added into appropriate
wells. Covered well and incubated for 2.5 h at room tempera-
ture. The solution was discarded and washed 4 times with 1·
wash solution (200 ll each). 100 ll of 1· prepared biotinylated
antibody was added to each well and incubated for 1 h at room
temperature. The solution was discarded and washed 4 times
with 1· wash solution (200 ll each). 100 ll of prepared Strep-
tavidin solution was added to each well and incubated for
45 min at room temperature. The solution was discarded and
washed 5 times with 1· wash solution (200 ll each). 100 ll
of TMB One-Step Substrate Reagent was added to each well
and incubated for 30 min at room temperature in the dark.
50 ll of Stop Solution was added to each well then the absor-
bance was read at 450 nm immediately.
Calculation of results
The concentration of TIMP-1 was calculated from the stan-
dard curve.
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Quantitative data were presented as means and standard devi-
ation (SD) values. Student’s t-test was used for comparisons
between means of two groups.Mann–Wihitney U-test was used
to compare between smoking indices of symptomatic and a
symptomatic smokers. Paired t-test was used to compare
between pulmonary function tests before and after the use of
bronchodilators in the smokers (with symptoms) group. One
way ANOVA (analysis of Variance) was used to compare
between means of the three groups. Qualitative data were pre-
sented as frequencies and percentages. Chi-square (x2) test was
used for studying the comparisons between different qualita-
tive variables. Pearson’s correlation coefﬁcient was used to
determine signiﬁcant correlations between the different vari-
ables. The signiﬁcance level was set at P 6 0.05. Statistical
analysis was performed with SPSS version 19.0 (statistical
package for scientiﬁc studies) for windows.
Results
Forty subjects were included in this study and were classiﬁed
into 3 groups; 20 patients known to have COPD who were
subdivided into mild, moderate, severe and very severe COPD
cases according to (GOLD, 2013), 10 apparently healthy smok-
ers and 10 healthy non smoker individuals (control). Patients
demographic and laboratory data were seen in table (1). There
was no statistical signiﬁcant difference between the three
groups as regards age. All patients and healthy subjects
included in this study were males. Mean number of cigarettes
smoked in COPD patients and smoking indices were statisti-
cally signiﬁcantly higher than the healthy smokers group
(Table 1).
In the COPD group all spirometric parameters were
decreased. But in the healthy smokers group the FEV1%,Table 1 Patient demographic data and smoking indices.
Age in years, mean ± SD S
M
Group I (COPD) 55.3 ± 6.6 2
Group II (healthy smokers) 52.4 ± 8.5 1
Group III (Healthy non smokers) 50.7 ± 6.1 1
p value 0.219





Mean ± SD Mean ± SD
FEV1 % 44.3 ± 17.3 80.1 ± 4.7
FVC % 55.8 ± 16.7 81.7 ± 4.9
FEV1/FVC % 54.2 ± 9.7 76 ± 6.8
FEF25–75 % 27.7 ± 16.5 67.9 ± 33.6
FEF50 % 25.4 ± 14.5 61.7 ± 30.9
PEF % 31.1 ± 8.7 51.8 ± 17.4
MVV % 31.1 ± 12.3 58.1 ± 15.9FVC% and FEV1/FVC% were preserved in contrast to
FEF25–75%, FEF50%, PEF% and MVV% were decreased
(table 2).Discussion
COPD is associated with a chronic inﬂammatory response,
predominantly in small airways and lung parenchyma, which
is characterized by increased number of macrophages, neutro-
phils, and T lymphocytes. Many proteases are also involved in
the inﬂammatory process and are responsible for the destruc-
tion of elastin ﬁbers in the lung parenchyma, which is the
hallmark of emphysema. The identiﬁcation of inﬂammatory
mediators and understanding their interactions are important
for the development of anti-inﬂammatory treatments for this
important disease [6].
Healthy non smokers group and healthy smokers group
had statistically signiﬁcantly higher mean FEV1%, FVC% &
FEV1/FVC% ratio than the COPD group. It also showed that
the non smokers group had statistically signiﬁcantly higher
mean FEF25–75%, FEF50%, PEF% and MVV% followed by
the healthy smokers group and the COPD group which
showed the lowest values which means that there is early affec-
tion of the small airways in the healthy smokers group which is
in line with [35] (table 2).
As regards MMP-9, the COPD group showed highly statis-
tically signiﬁcant highest mean MMP9, and MMP9/TIMP-1
ratio compared to healthy smokers group and healthy non
smokers group (table 3). These ﬁndings were in line with [36]
who found that sputum MMP-9 concentrations were increased
in COPD subjects compared to healthy never smoked but were
similar to healthy smokers. In addition, [37] in his study about
noninvasive biomarkers for early smoking related lung disease,
concluded that long-term smoking increased the levels of
MMP-9 and MMP-9/TIMP-1, suggesting that an imbalanceex
ale/female
Smoking indices (Mean ± SD)
NO Duration Smoking index
0/0 29 ± 11.43 31.45 ± 9.29 925 ± 437.2
0/0 17 ± 6.33 28.9 ± 9.24 475 ± 213.8
0/0 0 0 0
0.005 0.540 0.007




94 ± 1.8 <0.001
90.5 ± 2.9 <0.001
82.4 ± 1.9 <0.001
91.2 ± 4.7 <0.001
88.2 ± 8.1 <0.001
87.6 ± 5.9 <0.001
84.9 ± 6.1 <0.001
Table 3 Sputum MMP-9, TIMP-1 and their ratio in the three groups.
COPD group n= 20 Healthy smokers group n= 10 Healthy non smokers group n= 10 P-value
Mean ± SD Mean ± SD Mean ± SD
MMP9 (ng/ml) 194.4 ± 100.6 104.5 ± 42.1 34.5 ± 36.1 0.001
TIMP-1 (ng/ml) 115 ± 55.5 145.3 ± 35.1 192.7 ± 37.7 <0.001
MMP9/TIMP-1 1.7 ± 0.9 0.7 ± 0.3 0.2 ± 0.2 <0.001










Mean ± SD Mean ± SD Mean ± SD Mean ± SD
MMP9 (ng/ml) 71.5 ± 17.7 127.8 ± 88.3 161 ± 78.2 237.3 ± 122.1 0.101
TIMP-1 (ng/ml) 99.3 ± 0.0 95.4 ± 73.3 89.4 ± 72.2 80.4 ± 27.6 0.779
MMP9/TIMP-1 0.7 ± 0.18 1.3 ± 0.55 1.8 ± 0.61 2.9 ± 0.61 <0.001






Healthy non smoker group
n= 10
(r) P (r) P (r) P
FVC% 0.364 0.115 0.449 0.193 0.097 0.790
FEV1/FVC% 0.274 0.243 0.090 0.804 0.154 0.672
FEF25–75% 0.456 0.043* 0.222 0.537 0.294 0.410
FEF50% 0.466 0.039* 0.341 0.335 0.383 0.274
PEF% 0.222 0.346 0.135 0.709 0.425 0.221
MVV% 0.413 0.070 0.378 0.282 0.375 0.285
Cigarette no. 0.026 0.914 0.242 0.500
Smoking duration 0.152 0.521 0.218 0.544
Smoking index 0.076 0.751 0.059 0.871
\ Less than 0.05 signiﬁcant.






Healthy non smokers group
n= 10
(r) P (r) P (r) P
FVC% 0.025 0.918 0.460 0.181 0.233 0.518
FEV1/FVC% 0.031 0.898 0.319 0.370 0.347 0.325
FEF25–75% 0.058 0.809 0.361 0.306 0.101 0.782
FEF50% 0.004 0.986 0.507 0.135 0.194 0.592
PEF% 0.269 0.251 0.318 0.370 0.431 0.214
MVV% 0.038 0.875 0.278 0.438 0.297 0.404
Cigarette no. 0.306 0.190 0.317 0.372
Smoking duration 0.390 0.089 0.555 0.096
Smoking index 0.452 0.045* 0.294 0.409
\ Less than 0.05 signiﬁcant.
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but also in the systemic inﬂammatory process.As regards TIMP-1, it was found that healthy non smokers
group showed statistically signiﬁcant highest mean TIMP-1






Healthy non smokers group
n= 10
(r) P (r) P (r) P
FVC% 0.664 0.001** 0.405 0.245 0.472 0.169
FEV1/FVC% 0.195 0.411 0.405 0.246 0.161 0.657
FEF25–75% 0.537 0.015* 0.384 0.273 0.732 0.016*
FEF50% 0.552 0.012* 0.472 0.168 0.682 0.030
PEF% 0.552 0.012* 0.483 0.157 0.018 0.960
MVV% 0.598 0.005* 0.280 0.434 0.341 0.335
Cigarette no. 0.127 0.595 0.085 0.815
Smoking duration 0.197 0.405 0.600 0.067
Smoking index 0.199 0.401 0.523 0.121
\ Less than 0.05 signiﬁcant.
\\ Less than 0.001 highly signiﬁcant.
866 S.A. Esa et al.compared to COPD group and healthy smokers group (table
3). This result was in agreement with many studies [30,38].
In the COPD group, mean sputum MMP9/TIMP-1 ratio
was statistically signiﬁcant different between COPD cases with
the highest mean was found in cases with very severe COPD
cases and gradually decrease in sever, moderate and mild cases
(table 4).
Table 5 shows the correlation between sputum MMP9 and
different variables in the three groups. There was statistically
signiﬁcant negative correlation between sputum MMP9 and
(FEV1%, FEF25–75%, FEF50%).This result was in line with
[36,38–41].
Table 6. shows the correlation between sputum TIMP-1
and different variables in the three groups. There was a
statistically signiﬁcant negative correlation between sputum
TIMP-1 and smoking index in COPD group.
Table 7 shows the correlation between sputum MMP9/
TIMP-1 ratio and different variables in the three groups. There
was a statistically signiﬁcant negative correlation between spu-
tum MMP9/TIMP-1 ratio and (FVC%, FEF25–75%, FEF50%,
PEF%, MVV%) in COPD group as well as a statistically sig-
niﬁcant positive correlation with FEF25–75% in healthy non
smokers group. These results agreed with [30,41].
Conclusions
Sputum MMP-9 level in COPD patients showed statistically
signiﬁcant highest means followed by healthy smokers fol-
lowed by healthy non smokers group while sputum TIMP-1
level showed statistically signiﬁcant highest means in healthy
non smokers group followed by healthy smokers group fol-
lowed by COPD group. Sputum MMP-9/TIMP-1 ratio and
sputum total leucocytic counts showed statistically signiﬁcant
highest means in smokers (COPD and healthy smoker groups)
compared to non smokers group.
COPD is characterized by an imbalance between MMP-9
and TIMP-1 which may play an important role in the patho-
genesis of tissue remodeling and airway obstruction.
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